This notice issues targeted corrections to the Materials and Methods section titled "III: In Vivo study for Therapeutic potential of RDV‑bP against SARS virus, toxicity and stability in vivo." The correction clarifies that the phrase “Route of Administration (Table 1)” that appeared in this subsection should have been removed. No other procedural steps or experimental parameters beyond this phrasing change are reported in the correction notice.
The correction replaces an erroneous first sentence in the Sublingual paragraph under the bulleted point "Administration of test articles." The corrected sentence is provided exactly as reported in the notice:
NV − −387, NV–387-RDV-bP-and placebo for the gummy preparations were administered as a paste and painting the inner cavity of mouth by the use of a tuberculin syringe with no needle as per schedule and quantities in Table 1.
This replacement clarifies how the gummy preparations and placebo were delivered sublingually in the in vivo study. The correction does not add additional operational details beyond the wording above and refers readers to Table 1 of the original article for schedule and quantities.
A labeling error in Figure 6 of the original publication has been corrected. The notice provides the corrected figure images (downloadable PNG and TIFF) and republishes the figure legend. The correction is limited to the figure labeling; the notice does not report changes to the underlying data or to the experimental outcomes beyond correcting the label.
The corrected Figure 6 legend is reproduced in the correction notice and reports the following experimental context:
Title/Description: Antiviral Efficacy of RDV‑bP on NL63‑Infected Rats: Survival of Male and Female rats infected with NL‑63 SARS virus and treated with NV387, NV387‑RDV, NV387‑RDV‑bP and RDV‑SBECD (GLD).
Data reporting: Values are the mean ± SD from 3 experiments. Statistical analyses were done from two independent experiments done in duplicate.
Significance markers as listed in the legend: *: p < 0.5; **: p < 0.1; ***: p < 0.05.
The correction notice presents the corrected figure image and associated legend exactly as provided; no numerical survival values, curves, or additional analyses are added or altered in the correction beyond correcting the label.
This correction was published September 22, 2026, with DOI 10.1371/journal.pone.0359020. The correction explicitly pertains to the original article: Chakraborty A, Diwan A, Chiniga V, Arora V, Thakur Y, Tatake J, et al., Remdesivir‑bisPropionate, a better derivative of remdesivir against SARS‑CoV‑2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential, PLoS One. 2026;21(2):e0324811.
The correction is distributed under the Creative Commons Attribution License, consistent with the journal’s open access policy.
The correction notice lists the original article reference and links to the full article (DOI and PubMed identifiers as included in the notice). The correction is explicitly tied to that original publication and limits its amendments to the described Materials and Methods phrasing, the corrected sublingual administration sentence, and the corrected labeling of Figure 6.
Note on content and scope
All material in this rewritten correction summary is drawn from the PLOS ONE correction notice. No new experimental findings, numerical results beyond what the correction provided, or recommendations beyond the stated textual and figure label corrections have been introduced. The correction does not report altered experimental outcomes or new PK/PD data; it confines changes to the methods wording and to the figure label and legend as described in the source notice.